Grifols’Novartis blood testing buy to up Dx revenue five-fold
This article was originally published in Clinica
Executive Summary
Spanish group Grifols will inflate significantly its diagnostics offering with the agreed $1.675bn acquisition of the blood transfusion diagnostics business of pharma giant Novartis. Once the deal closes – which is expected to happen in the first half of 2014 – Grifols’ diagnostic division will account for over 20% of its sales, compared to around 4% currently, with a turnover of almost $1bn.